National Antiretroviral Treatment Guidelines

Objectives

Sierra Leone’s National Antiretroviral Treatment Guidelines provide a comprehensive public-health framework for expanding access to antiretroviral therapy (ART), integrating HIV prevention, care and treatment, and supporting healthcare workers managing people living with HIV/AIDS.[1][2][3]The guidelines seek to improve quality of life, preserve or restore immune function, reduce HIV-related morbidity and mortality, achieve durable viral-load suppression, prevent drug resistance and treatment failure, and reduce HIV transmission, stigma and discrimination.[2][3]

• Expand access to lifelong ART for adults, adolescents, children, pregnant and breastfeeding women, using clinically appropriate eligibility criteria, treatment regimens and monitoring.[4][5][6][7][8][9]
• Strengthen prevention through HIV testing and counselling, safer behaviour, prevention of mother-to-child transmission, occupational post-exposure prophylaxis, co-trimoxazole prophylaxis and adherence support.[2][3][10][11][12]
• Provide combination therapy that maximises potency and tolerability while minimising prior drug exposure, adverse effects and cross-resistance.[3][13][14]
• Support comprehensive care through nutrition, psychosocial assistance, family and community involvement, and measures to address treatment readiness and long-term adherence.[4][6][7][15][11]
• Manage co-infections and HIV-related conditions, including tuberculosis, hepatitis B and C, immune reconstitution syndrome and opportunistic infections.[4][5][16][17]
• Apply age-appropriate paediatric care to improve survival and reduce HIV-related morbidity, including diagnostic confirmation, clinical staging, growth monitoring and tailored first- and second-line treatment.[17][18][8][19]

The guidelines also establish clinical staging and diagnostic criteria for HIV-related disease in adults, adolescents and children, distinguishing presumptive clinical assessment from definitive confirmation through laboratory, imaging, microbiological, histological or molecular investigations where required.[20][21][22][23][24][25][26]A broader quantified programme target framework is not specified in the supplied material.[27][28]

Implementation

Implementation combines decentralised clinical delivery, standardised treatment regimens, tiered laboratory services, regular patient follow-up, counselling and data use. ART should be embedded in functioning, affordable health services and support networks with trained prescribers, diagnostic capacity, reliable quality-assured medicine supplies, laboratory services, voluntary HIV counselling and testing, and follow-up counselling.[7]Treatment decisions require patient readiness and informed acceptance, supported by baseline medical, psychosocial, nutritional and clinical assessment.[7][29]

• Assess eligibility using clinical stage, CD4 cell count and relevant clinical criteria, with alternative staging and lymphocyte-count criteria where CD4 testing is unavailable.[29][30][8]
• Initiate recommended first-line combination therapy and change to second-line regimens after confirmed toxicity or treatment failure, retaining active medicines and introducing new effective drugs where possible.[13][14][31][19]
• Adapt regimens for pregnancy, breastfeeding, contraception needs, paediatric age and weight, tuberculosis treatment containing rifampicin, hepatitis co-infection and other clinically significant drug interactions.[16][17][19][9][10]
• Use a tiered laboratory package according to technical and financial capacity, beginning with HIV testing and haemoglobin or haematocrit measurement, adding safety tests where feasible, and using CD4 and viral-load testing when resources permit.[32][30]
• Schedule follow-up after treatment initiation and at regular intervals for clinical assessment, adherence counselling, toxicity detection, management of opportunistic infections and assessment of treatment response or failure.[14][33][34][35]
• Enable district hospitals to initiate and follow up ART patients, permit private-clinic follow-up where expertise and links to experienced providers are available, and engage community-based organisations in adherence support through effective referral networks.[33]
• Promote adherence through pre-treatment education, personal adherence plans, treatment supporters, family and community participation, repeated counselling and increased contact where adherence is poor.[13][18][12][36]

Clinical monitoring relies on examination, clinical staging, adherence review and laboratory testing for immunological response, viral activity, drug toxicity and co-infections.[32][13][33]CD4 counts and viral load are used to assess immune recovery and treatment efficacy where available, while treatment failure may be assessed through virological, immunological and clinical progression criteria.[30][31]Paediatric monitoring additionally covers growth, neurodevelopment, CD4 percentage, viral load and treatment-refractory infections.[19][34]

ART data should be collected from implementation actors on treatment access, screening and eligibility, clinic attendance and defaulting, adverse effects, treatment failure and adherence.[33]Facilities should send data through district medical officers to the HIV/AIDS Health Sector Response, enabling districts to identify bottlenecks and national actors to improve policies and guidelines.[33]Development of the guidelines was coordinated through the National HIV/AIDS Secretariat’s Health Sector Response, with contributions from the Ministry of Health and Sanitation, professional practitioners, people living with HIV/AIDS, the World Health Organization and other partners.[2]

Financial and resource constraints shape delivery, particularly laboratory monitoring: CD4 and viral-load testing are described as valuable but often too costly for routine use in resource-limited settings, and monitoring costs may exceed the cost of antiretroviral regimens.[30][14][33]The supplied material does not specify an implementation timetable, detailed governance structure, budgets, procurement arrangements or quantified financing plan.[28][2][7]

Monitoring & Evaluation

Monitoring is primarily a clinical and laboratory system for assessing HIV disease severity, treatment eligibility, response, toxicity, adherence and treatment failure across adults, adolescents, pregnant women and children. It is complemented by facility-to-district-to-national ART data reporting intended to identify delivery bottlenecks and inform policy and guideline improvement.[3][32][33]

• Conduct baseline assessment before ART, including medical history, physical examination, clinical staging, counselling, demographic information, current medicines and symptoms, pregnancy or contraceptive needs where relevant, and laboratory investigations.[29]
• Use WHO clinical stages I to IV, clinical symptoms, treatment response and diagnostic confirmation methods to assess disease severity and HIV-related conditions. Confirmatory methods may include laboratory testing, microscopy, culture, histology, radiography, antigen testing, endoscopy, bronchoscopy and polymerase chain reaction testing.[37][20][21][22][23]
• Monitor immune status using CD4 cell count or, for younger children, CD4 percentage; CD4 counts are used to assess immunological damage and recovery, while absolute counts are difficult to interpret for children under eight years.[30][34]
• Use viral-load testing, where resources permit, to assess viral activity and treatment effectiveness. It is optional in resource-limited settings, while CD4 and viral-load testing may be too expensive for routine use in many high-prevalence, resource-limited settings.[30][13]
• Apply laboratory monitoring for treatment safety, including haemoglobin or haematocrit as a minimum test, and, where capacity permits, blood-cell counts, liver enzymes, creatinine or blood urea nitrogen, glucose, bilirubin, amylase and lipids.[30]
• Schedule clinical follow-up after ART initiation, with one approach specifying visits at one month and then every three to four months, with monthly visits encouraged where feasible to support adherence.[14]Another schedule specifies reviews at weeks 2, 4, 8 and 12 for children, then every two to three months after stabilisation.[34]
• Review treatment response, opportunistic infections, drug toxicity, adherence and treatment failure during follow-up; conduct clinical reviews during the first weeks and months of ART and then three-monthly, with longer four-to-six-month intervals possible where results remain stable.[33][35]
• Assess adherence at every health-centre visit, investigate it when a regimen fails, and involve treatment supporters, relatives, friends, community personnel and counsellors in ongoing support.[12][36]

Treatment failure is assessed through virological, immunological and clinical criteria. Virological failure includes repeated HIV RNA above 400 copies per microlitre after 24 weeks or above 50 copies after 48 weeks among treatment-naive patients starting therapy; immunological failure includes inadequate CD4 recovery or decline below baseline; and clinical progression includes new or recurrent WHO stage 3 or 4 events after at least three months of therapy.[31][16]In children, failure assessment also considers poor or declining growth, loss of neurodevelopmental milestones, encephalopathy, and recurrent treatment-refractory infections.[19][34]

Additional targeted monitoring is specified for particular interventions. Pregnant women taking nevirapine require close observation, particularly during the first 12 weeks, for hepatic toxicity and serious rash.[10]Co-trimoxazole prophylaxis requires baseline patient data, monitoring of adverse reactions and local antimicrobial sensitivity, and assessment of potential effects on sulfadoxine/pyrimethamine effectiveness for malaria.[15]Occupational exposure management includes prompt reporting and post-exposure assessment, while adherence is monitored continuously during HIV treatment.[12][36]

ART data collection covers treatment access, screening and eligibility, attendance and defaulting, adverse or toxic effects, treatment failure and adherence. Facilities forward data through the district medical officer to the HIV/AIDS Health Sector Response; district-level information is used to address bottlenecks, while national-level information informs programme policies and guidelines.[33]The supplied material does not specify a consolidated national indicator set, reporting frequency, surveillance architecture, evaluation design, targets, named accountability bodies or formal sanctions beyond these clinical, data-management and programme-improvement mechanisms.[4][6][33]

Costing & Financing

Costing and financing information is limited. The guidelines recognise that sustained ART requires long-term resources, affordable health services, reliable supplies of quality medicines, laboratory capacity, counselling, nutritional support and follow-up care.[7]They also note that the availability of technical and financial resources should determine the laboratory-monitoring package used in a given setting.[32]

• Mobilise moral and financial assistance for guideline production from the Government of Sierra Leone, the World Health Organization, the United Nations Children’s Fund, the Global Fund and the Joint United Nations Programme on HIV/AIDS.[2]
• Prioritise a minimum laboratory package of HIV antibody testing and haemoglobin or haematocrit measurement where resources are constrained, while adding more tests as capacity permits.[30]
• Recognise that CD4 and viral-load tests are useful for care but may be unaffordable for routine use in many resource-limited settings, particularly where HIV prevalence is high.[30]
• Consider the cost implications of viral-load testing and the finding that monitoring costs may exceed the purchase cost of antiretroviral regimens.[13][33]
• Prefer fixed-dose antiretroviral combinations where suitable because they are described as cheaper, easier to use and supportive of adherence by reducing pill burden.[13][14]
• Provide infection-prevention resources, including educational materials, disposable gloves, needles, syringes and sharps containers, although no prices or allocations are given.[11][12]

The guidelines identify determination of a minimum monitoring schedule that does not compromise care as an area requiring further study, pending stronger clinical-trial evidence.[14][33]No document-wide budget, expenditure plan, costed implementation framework, quantified allocation, monetary funding gap, financing timetable, economic model or price schedule is specified in the supplied material.[27][4][5][6][2]